BCPC — Q2 2026 Financial Report Analysis

Balchem Q2 2026: record sales and profit, with all three segments growing and Animal Nutrition doing the heavy lifting on profit growth

Balchem, which makes specialty ingredients for food, supplements, animal feed and medical sterilisation, reported second-quarter 2026 net sales of $284.0 million, up 11.2% from $255.5 million a year earlier. Net earnings rose 16.6% to $44.6 million and diluted earnings per share (EPS — profit divided by the number of shares) rose from $1.17 to $1.39. Growth came mostly from selling more product (volume and mix) in its largest segment, Human Nutrition & Health, plus higher prices in Animal Nutrition & Health and Specialty Products; currency added only about half a percentage point or less in most segments. Profit grew faster than sales because operating costs grew more slowly than revenue and interest expense fell.

At a glance

• Sales +11.2% to $284.0M — a company record, with every segment up (Human Nutrition & Health +10.0%, Animal Nutrition & Health +15.0%, Specialty Products +8.9%).
• Operating margin 20.9% vs 20.1% — about 70 basis points of improvement, almost all of it from overhead growing slower than sales rather than from a better gross margin (36.5% vs 36.4%).
• Operating cash flow $46.7M vs net earnings $44.6M — profits are turning into cash, though free cash flow slipped to $36.2M from $40.7M as capital spending rose and inventory built up.

Key figures

Operating margin is the share of sales left after paying for production and running the business, before interest and tax. Adjusted EBITDA is the company's own profit measure that also strips out depreciation, amortisation, stock-based pay and deal costs.

For the first half of 2026, sales were $554.7 million (+9.6%), net earnings $84.9 million (+12.7%) and diluted EPS $2.63 versus $2.30 (+14.3%), so the second quarter was faster than the first.

Segment performance

Human Nutrition & Health (62% of sales) supplies nutrients such as choline and minerals plus food and beverage ingredient systems. Sales grew 10.0%, and the 10-Q splits that into 7.0 points from selling more and a richer mix of products, 2.7 points from price and 0.4 points from currency — so this is mostly genuine demand, not price increases. Operating profit rose $4.0 million, from a $5.7 million gross-margin gain partly eaten by $1.7 million of higher operating expenses, mostly pay ($0.9 million) and amortisation.

Animal Nutrition & Health is the swing segment. Sales rose 15.0%, split almost evenly between volume/mix (7.9 points) and price (6.6 points), across both monogastric (pigs, poultry) and ruminant (dairy cattle) markets. Profit jumped 48.7% to $5.2 million, but from a low base: the segment still earns only about 8 cents of operating profit per dollar of sales, against 24 cents in Human Nutrition and 32 cents in Specialty Products. The company says gains were "partially offset by certain higher manufacturing input costs" — a reminder that a large share of this segment's sales growth came from pricing, which tends to follow input costs rather than lead them.

Specialty Products (performance gases such as ethylene oxide for sterilising medical devices, and chelated minerals for crops) grew 8.9%, with price (4.3 points) contributing more than volume (3.7 points). Operating margin reached 31.8%, the highest of the three segments.

Where the extra profit came from

Gross margin (sales minus the direct cost of making the product) only edged up from 36.4% to 36.5%. Management attributes it to "sales growth and manufacturing efficiencies, partially offset by certain higher manufacturing input costs." The bigger margin lever was overhead: operating expenses grew 6.7% (to $44.5 million, mostly $2.9 million of higher compensation costs) while sales grew 11.2%, so expenses fell from 16.3% to 15.7% of sales.

Below the operating line, interest and other expenses dropped from $2.4 million to $1.4 million; net interest expense fell to $1.9 million from $2.8 million on lower borrowings and lower rates.

What the headline numbers hide

• EPS grew faster than profit, partly from buybacks. Net earnings rose 16.6% but EPS rose 18.8%, because diluted shares fell 1.5% (32.2 million vs 32.7 million). Balchem bought back $28.8 million of stock in the quarter and $114 million over the past twelve months. Lower interest cost also helped. Pulling the other way, the tax rate rose to 22.8% from 21.9% because of smaller stock-compensation tax benefits. Net of these, the large majority of EPS growth came from operations.
• The GAAP vs adjusted gap is small and steady. Adjusted EPS ($1.49) is $0.10 above GAAP EPS ($1.39), the same $0.10 gap as a year ago. Almost all of it is $4.4 million of amortisation of intangible assets from past acquisitions — a recurring, non-cash charge. Deal costs ($22,000) and deferred-compensation adjustments ($0.6 million) are minor. Note that adjusted EBITDA also adds back $5.9 million of stock-based pay, which is a real cost to shareholders.
• Cash conversion is fine; free cash flow dipped. Q2 operating cash flow of $46.7 million was 1.05x net earnings, and the first half was $86.8 million vs $84.9 million of earnings. Free cash flow (operating cash flow minus capital spending) fell to $36.2 million from $40.7 million because capital expenditures rose to $10.5 million from $6.6 million, and working capital absorbed $35.2 million in the first half against $22.5 million a year earlier.
• Inventory is growing much faster than sales. Inventories rose 22.9% in six months, from $131.4 million at December 31, 2025 to $161.6 million at June 30, 2026, with raw materials up 25% and finished goods up 23%, while first-half sales grew 9.6% year over year. Receivables rose a more modest 3.7% to $149.0 million. The filing does not explain the build; the inventory reserve for obsolete or excess stock also rose to $4.5 million from $3.4 million. It may be deliberate (stocking up ahead of demand or against supply disruption from the Middle East conflict the 10-Q mentions), but it is the one number to watch in Q3: if sales don't keep pace, it becomes a cash drag or a write-down risk.
• No one-offs of note in either year: restructuring was a small $0.2 million credit in Q2 2025 and nothing this year.

Takeaway: This was a volume-led quarter, not a price-led one, in Balchem's biggest segment — Human Nutrition & Health grew 7 points from selling more and only 2.7 from price — and that is the more durable kind of growth. The margin gain came from overhead leverage rather than richer gross margins, and the 23% inventory build is the main caveat on otherwise clean results.

Balance sheet and capital

Debt is low. The revolving loan stood at $152.0 million and net debt (borrowings minus cash) at $88.8 million, which Balchem puts at 0.3 times trailing adjusted EBITDA. On July 24, 2026 it extended its credit facility to July 2031 and raised it from $550 million to $650 million. The 10-Q states the company is "actively pursuing additional acquisition candidates," so the larger facility reads as dry powder for a deal. During Q2 it also brought home $23.5 million from its Belgian subsidiary to repay US debt.

Risks the company flags

• Middle East conflict: the 10-Q cites tensions involving Iran as a source of higher energy, raw material and freight costs and shipping disruption.
• Tariffs: after the February 2026 Supreme Court ruling striking down IEEPA tariffs, Balchem has filed for refunds where it was importer of record; it cannot yet estimate the impact but does not expect it to be material.
• Ethylene oxide regulation remains a standing risk to the sterilisation-gas business in Specialty Products.

Outlook

Balchem does not give numerical guidance; management said it remains "confident in the long-term growth outlook." Our read: with every segment growing, volume-led gains in Human Nutrition & Health and Q2 growth accelerating from Q1, the business is on track for a year of roughly 10% sales growth and mid-teens EPS growth if the second half resembles the first. The things to watch in Q3 (the 10-Q is likely due around the end of October 2026) are whether input-cost pressure from the Middle East starts to squeeze the flat gross margin, whether Animal Nutrition's margin recovery holds as price gains annualise, whether inventory comes back down, and whether the expanded credit line is used for an acquisition.

Source: Balchem Form 10-Q for the quarter ended June 30, 2026, and the Q2 2026 earnings release (Form 8-K Exhibit 99.1), filed July 31, 2026.